Vitrolife AB (CHIX:VITRS) Short-Term Debt: kr0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:VITRS Vitrolife AB CHIX:VITRS
75 GF Score
Price kr86.38
GF Value kr185.92
! 6 Warning Signs
View Full Analysis

What is Vitrolife AB Short-Term Debt?

Vitrolife AB CHIX:VITRS 75 Short-Term Debt is kr0 Mil as of Jun. 2026. GuruFocus rates CHIX:VITRS with a GF Score™ of 75/100 and a GF Value™ of kr185.92. The stock has 6 warning signs investors should review.

Vitrolife AB's Short-Term Debt for the quarter that ended in Jun. 2026 was kr0 Mil.

Vitrolife AB's annual Short-Term Debt increased from Dec. 2023 (kr114 Mil) to Dec. 2024 (kr115 Mil) but then declined from Dec. 2024 (kr115 Mil) to Dec. 2025 (kr0 Mil).

Vitrolife AB Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Vitrolife AB Short-Term Debt Related Terms

Vitrolife AB Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Vitrolife AB's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitrolife AB Short-Term Debt Chart

Vitrolife AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 429.00 153.00 114.00 115.00 0.00

Vitrolife AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 111.00 0.00 0.00 0.00 0.00
CHIX:VITRS
75GF Score
Vitrolife AB CHIX:VITRS
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of kr0 Mil mean?
Vitrolife AB (CHIX:VITRS) has a Short-Term Debt of kr0 Mil as of Jun. 2026.
Is Vitrolife AB's Short-Term Debt too high?
Vitrolife AB's current Short-Term Debt is kr0 Mil. Overall, Vitrolife AB has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's Short-Term Debt compare to ABT and SYK?
Vitrolife AB's Short-Term Debt of kr0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Devices & Instruments company?
A good Short-Term Debt depends on the Medical Devices & Instruments industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Vitrolife AB's current Short-Term Debt is kr0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Vitrolife AB (CHIX:VITRS) has a current Short-Term Debt of kr0 Mil. The stock's GF Value™ is kr185.92, compared to a current price of kr86.38 — trading 53.5% below its estimated fair value. The current Short-Term Debt is kr0 Mil. Vitrolife AB's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Vitrolife AB (CHIX:VITRS), the current Short-Term Debt is kr0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vitrolife AB (CHIX:VITRS) Overvalued in 2026?

Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued. The current stock price of kr86.38 is trading 53.5% below its estimated GF Value™ of kr185.92.

Key valuation signals for CHIX:VITRS:

  • Short-Term Debt: kr0 Mil
  • GF Value™: kr185.92 vs. price of kr86.38 (53.5% below fair value)
  • GF Score™: 75/100 with 6 warning signs

No single metric tells the full story. See the CHIX:VITRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vitrolife AB Business Description

Address Box 9080, Gothenburg, SWE, 400 92
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
75GF Score

Get the complete analysis for CHIX:VITRS

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr86.38
Price
kr185.92
GF Value